 |
|
Our Pipeline
|
Onconome’s current product pipeline consists of five technologies under exclusive option to license from major universities in the US and Europe plus technologies being developed in the company’s own lab. These technologies include tests for the early detection of prostate and colon cancer, prognostics for assessing the aggressiveness of prostate and colon cancer and tests for the early detection of diabetic kidney disease.
Optioned Technologies
Technologies Under Consideration
- Pan-Cancer Metastatic Marker (NDA signed)
- NCI Prognostic Marker for Breast Cancer (NDA signed)
- Multiplexed Markers for Breast Cancer Detection (NDA signed)
- Age Related Macular Degeneration Marker (NDA signed)
- Pan Cancer Screening and Detection Marker (NDA signed)
- Early Stage Lung Cancer Detection Marker (NDA signed)
- Cardiovascular Prognostic Marker (NDA signed)
|
|
|
|
|
|
|
|
|
|
